行情

ADXS

ADXS

Advaxis
NASDAQ

实时行情|Nasdaq Last Sale

0.7840
-0.0105
-1.32%
交易中 11:11 01/29 EST
开盘
0.8000
昨收
0.7945
最高
0.8200
最低
0.7830
成交量
100.01万
成交额
--
52周最高
10.80
52周最低
0.2051
市值
4,721.35万
市盈率(TTM)
-9.7270
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADXS 新闻

  • Advaxis down 15% on equity offering
  • seekingalpha.01/21 22:51
  • Mid-Afternoon Market Update: CSS Industries Surges Following Acquisition News; Advaxis Shares Slide
  • Benzinga.01/21 20:05
  • Mid-Day Market Update: Dow Falls Over 100 Points; Genprex Shares Spike Higher
  • Benzinga.01/21 17:07
  • Mid-Morning Market Update: Markets Open Lower; Halliburton Beats Q4 Estimates
  • Benzinga.01/21 15:14

更多

所属板块

生物技术和医学研究
0.00%
制药与医学研究
+0.40%

热门股票

名称
价格
涨跌幅

ADXS 简况

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
展开

Webull提供Advaxis, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。